FDA Warns Bayer After Routine Inspection of Facilities

The U.S. Food and Drug Administration (FDA) sent a warning letter to Bayer about drug manufacturing practices at its German headquarters. The FDA’s complaints were triggered by a routine inspection in January of this year.

In a statement, the company said the regulatory agency has no evidence of risk to patient safety. As a result of this inspection and the time to complete the necessary corrective actions, Bayer expects temporary supply limitations on some of its products, including Adalat, Aspirin Cardio, Avelox, and Levitra.

Source: Reuters, February 14, 2018.

SHARE